Wegovy (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist licensed in the UK for weight management in adults with obesity or overweight with weight-related comorbidities
"A Trillion Dollar Drug" Huberman's most headline-worthy claim was about retatrutide's market potential and the regulatory dynamics around peptide access: "This is going to be a trillion dollar drug
Overall, the researchers estimated that GLP-1 use was associated with 12 fewer serious addiction-related events per 1,000 users
A lot of what we do when were taking a medication is replacing what were missing, said Valenton, emphasizing the Eastern medicine approach.
(Eden pricing verified at checkout, July 2026.) Start your GLP-1 program with PlexusDx One all-inclusive price covers your online provider visit, prescription, compounded medication, and shipping no membership, no hidden fees